Evidence map›Paper›PMID 39129004›Full record

ArticleMolecular medicine (Cambridge, Mass.)2024

Targeting AGTPBP1 inhibits pancreatic cancer progression via regulating microtubules and ERK signaling pathway.

Ding-Zhong Li, Zhe-Yu Yang, Asi Leng, Qian Zhang, Xiao-Dong Zhang, Yan-Chao Bian, Rui Xiao, Jian-Jun Ren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ER-Localized DeadenylaseExploration (Beijing, China) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ding-Zhong Li *Department of Hepatobiliary, Pancreatic and Splenic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, #1, Tongdao North Street, Huhhot, 010051, PR China.
Zhe-Yu Yang *Department of Hepatobiliary, Pancreatic and Splenic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, #1, Tongdao North Street, Huhhot, 010051, PR China.
Asi Leng *Medical Simulation Center, Inner Mongolia Medical University, Huhhot, 010059, PR China.
Qian ZhangDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, #1, Tongdao North Street, Huhhot, 010051, PR China.
Xiao-Dong ZhangDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, #1, Tongdao North Street, Huhhot, 010051, PR China.
Yan-Chao BianInner Mongolia Key Laboratory of Molecular Pathology, Inner Mongolia Medical University, #5, Xin Hua Street, Huhhot, 010059, PR China.
Rui XiaoInner Mongolia Key Laboratory of Molecular Pathology, Inner Mongolia Medical University, #5, Xin Hua Street, Huhhot, 010059, PR China. xiaorui79@hotmail.com.ORCID 0000-0002-8395-1041
Jian-Jun RenDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, #1, Tongdao North Street, Huhhot, 010051, PR China. renjj.ok@163.com.

Funding

Natural Science Foundation of Inner Mongolia Autonomous Region 2022MS08024Scientific projects of Inner Mongolia Medical University YKD2022MS015Scientific projects of Inner Mongolia Medical Universityy YKD2021MS024
6 · The paper itself

Abstract

backgroundAGTPBP1 is a cytosolic carboxypeptidase that cleaves poly-glutamic acids from the C terminus or side chains of α/β tubulins. Although its dysregulated expression has been linked to the development of non-small cell lung cancer, the specific roles and mechanisms of AGTPBP1 in pancreatic cancer (PC) have yet to be fully understood. In this study, we examined the role of AGTPBP1 on PC in vitro and in vivo.

methodsImmunohistochemistry was used to examine the expression of AGTPBP1 in PC and non-cancerous tissues. Additionally, we assessed the malignant behaviors of PC cells following siRNA-mediated AGTPBP1 knockdown both in vitro and in vivo. RNA sequencing and bioinformatics analysis were performed to identify the differentially expressed genes regulated by AGTPBP1.

resultsWe determined that AGTPBP1 was overexpressed in PC tissues and the higher expression of AGTPBP1 was closely related to the location of tumors. AGTPBP1 inhibition can significantly decrease cell progression in vivo and in vitro. Moreover, the knockdown of AGTPBP1 inhibited the expression of ERK1/2, P-ERK1/2, MYLK, and TUBB4B proteins via the ERK signaling pathway.

conclusionOur research indicates that AGTPBP1 may be a putative therapeutic target for PC.

Indexed as

CarboxypeptidasesGene Expression Regulation, NeoplasticMAP Kinase Signaling SystemMicrotubulesPancreatic NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGTP-Binding ProteinsHumansMaleMiceMiddle AgedAGTPBP1 protein, humanCarboxypeptidasesGTP-Binding ProteinsSerine-Type D-Ala-D-Ala CarboxypeptidaseAGTPBP1MAP1AMYLKPDACTubulin

Identifiers

PMID39129004
PMCPMC11318240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.